Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in mild cognitive impairment and mild Alzheimer's disease
NCT04795466Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2021
- Primary completion
- Mar 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Canakinumab with Placebo (2 arms). Primary endpoint: Neuropsychological Test Battery Z-score at 24 weeks. Started Oct 2021; status: terminated.
02
Drugs
canakinumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04795466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04795466.